Levaquin, Avelox Manufacturers Face New Peripheral Neuropathy Claims
The manufacturers of Levaquin and Avelox have been named defendants in two new lawsuits by patients who allegedly developed peripheral neuropathy due to their use. Both cases, which were filed earlier this month in the U.S. District Court, Eastern District of Pennsylvania, claim that the pharmaceutical companies had a duty to warn doctors and patients about this potential side effect, but failed to do so.
According to a complaint filed on August 5th, Denise Gubitosi was treated with Avelox in April 2013. She alleges that her use of the drug resulted in permanent peripheral neuropathy. Gubitos further claims that she could have avoided the debilitating disorder had Bayer and Merck & Co. properly disclosed this risk.
Plaintiff Michelin Rowel, who filed her Levaquin lawsuit on August 11th, claims that her use of the medication resulted in permanent nerve damage. Her lawsuit maintains that Levaquin is defective, dangerous to human health, unfit and unsuitable to be marketed and sold in commerce. She further charges that the antibiotic was marketed without proper warnings and directions as to the risks associated with its use.
Levaquin and Avelox are approved to treat serious bacterial infections, including pneumonia. They belong to a class of antibiotics called fluoroquinolones, which also includes Cipro and various generic brands.
Hundreds of peripheral neuropathy lawsuits have been filed aganst the manufacturers of Levaquin, Cipro and Avelox in courts around the U.S. Last year, all federally-filed claims were centralized in the U.S. District Court, District of Minnesota, where nearly 400 cases are now undergoing coordinated pretrial proceedings. Plaintiffs involved in the litigation assert that studies published as early as 1990 suggested a link between the use of fluoroquinolone antibiotics and the onset of peripheral neuropathy. However, mention of the condition was not noted on the drugs’ labels until 2004. Then, in August 2013, the U.S. Food & Drug Administration (FDA) ordered their manufacturers to strengthen the labels to better reflect the rapid onset of peripheral neuropathy symptoms, as well as the potential for permanent nerve damage.
This past May, the FDA ordered additional label changes, after an agency review confirmed that fluoroquinolone antibiotics are associated with a number of serious side effects, including those involving the tendons, muscles, joints, nerves and central nervous system. These complications are potentially permanent and can occur together, the FDA said.
Attorneys Now Evaluating Antibiotic Lawsuits
Bernstein Liebhard LLP is now offering free legal reviews to peripheral neuropathy victims who were diagnosed with the condition following treatment with Levaquin, Avelox or Cipro. To learn more, please call 877-779-1414.